VIDEO: ACR ‘packed with new knowledge’ in rheumatoid arthritis space
Click Here to Manage Email Alerts
WASHINGTON — In this video, Namrata Singh, MD, MSCI, spotlights three important abstracts in rheumatoid arthritis presented at ACR Convergence 2024.
“ACR, as you know, is always full and packed with new knowledge and definitely refreshing some of the older concepts that we’ve been thinking we are doing right and then all of a sudden we have some paradigm shifts,” Singh, an associate program adjunct assistant professor in the department of epidemiology and an assistant professor in the department of rheumatology at the University of Washington School of Public Health, told Healio.
The first presentation she discussed assessed whether it is necessary or not to hold biologic or JAK inhibitor medications to improve the efficacy of the COVID-19 booster in patients with RA or spondyloarthritis.
Singh also highlighted a randomized controlled phase 1a trial investigating the safety and efficacy of a non-T-cell receptor contacting peptide among patients with RA. She also mentioned a phase 2 randomized controlled trial evaluating the safety, efficacy and pharmacokinetics of abiprubart (Kiniksa Pharmaceuticals), an anti-CD40 antibody, in patients with RA.
“Several abstracts focused around newer therapies in rheumatoid arthritis,” Singh said.
Reference:
- Jenkins E, et al. Abstract #1678. Presented at: ACR Convergence 2024; Nov. 14-19, 2024; Washington, D.C.
- Li R, et al. Abstract #1677. Presented at: ACR Convergence 2024; Nov. 14-19, 2024; Washington, D.C.
- Mudano M, et al. Abstract #1718. Presented at: ACR Convergence 2024; Nov. 14-19, 2024; Washington, D.C.
Collapse
Healio Interviews
Click Here to Manage Email Alerts